Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
D-Cycloserine · 1 trial · 1 indication
The PAS is designed for patients with agoraphobia or panic disorder who are at least 15 years old. It can be used to determine the severity of the disorder or to examine therapeutic success. There is a self-rating and a clinician-rating version available with 14 items each, yet the items are the same in both versions. Answers are given on a five-point Likert scale from "0" to "4" with higher scores indicating a higher severity. For determination of the severity of the disorder, 13 items are summed up, only item "U" (asking if panic attacks occur expected or unexpected) is not considered, resulting in scores between 0 and 52. There are also five sub scores if only special contents are of interest: Panic attacks, agoraphobic avoidance, anticipatory anxiety, disability, and worries about health. For the present study the German version of the questionnaire is used.
| Arm | Type | Description |
|---|---|---|
| D-Cycloserine + CBT | EXPERIMENTAL | Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure |
| Placebo + CBT | PLACEBO_COMPARATOR | Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure |
| Name | Type | Description |
|---|---|---|
| CBT | BEHAVIORAL | 12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure |
| D-Cycloserine | DRUG | Administered for three times (50mg, oral) directly after exposure |
Inclusion Criteria: * written consent (as per AMG §40 (1) 3b) * diagnosis of agoraphobia; severity of the disorder due to the CGI should at least be "moderately ill" * age: 18-75 years * negative pregnancy test for premenopausal women and safe contraception (Pearlindex \< 1) during the study * acce...